Details
Stereochemistry | RACEMIC |
Molecular Formula | C11H15NO |
Molecular Weight | 177.2429 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@H]1NCCO[C@H]1C2=CC=CC=C2
InChI
InChIKey=OOBHFESNSZDWIU-GXSJLCMTSA-N
InChI=1S/C11H15NO/c1-9-11(13-8-7-12-9)10-5-3-2-4-6-10/h2-6,9,11-12H,7-8H2,1H3/t9-,11+/m0/s1
Phenmetrazine is an anti-obesity drug, which was discovered by Boehringer-Ingelheim in 1952 and approved by FDA under the name Preludin. Later on the drug was withdrawn from the market due to the reported cases of abuse. According to some studies, misuse of phenmetrazine turned many young addicts to crime. It is suggested that the drug exerts its effect by inhibiting the monoamine transport.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P31645 Gene ID: 6532.0 Gene Symbol: SLC6A4 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/17017961 |
7765.0 nM [EC50] | ||
Target ID: Q01959 Gene ID: 6531.0 Gene Symbol: SLC6A3 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/17017961 |
131.0 nM [EC50] | ||
Target ID: P23975 Gene ID: 6530.0 Gene Symbol: SLC6A2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/17017961 |
50.4 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseTreatment of obesity. |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
120 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6026786/ |
75 mg single, oral dose: 75 mg route of administration: Oral experiment type: SINGLE co-administered: |
PHENMETRAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6026786/ |
75 mg single, oral dose: 75 mg route of administration: Oral experiment type: SINGLE co-administered: |
PHENMETRAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
DEA NO. |
1631
Created by
admin on Fri Dec 15 15:28:27 GMT 2023 , Edited by admin on Fri Dec 15 15:28:27 GMT 2023
|
||
|
NCI_THESAURUS |
C47795
Created by
admin on Fri Dec 15 15:28:27 GMT 2023 , Edited by admin on Fri Dec 15 15:28:27 GMT 2023
|
||
|
NCI_THESAURUS |
C29728
Created by
admin on Fri Dec 15 15:28:27 GMT 2023 , Edited by admin on Fri Dec 15 15:28:27 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
8067
Created by
admin on Fri Dec 15 15:28:27 GMT 2023 , Edited by admin on Fri Dec 15 15:28:27 GMT 2023
|
PRIMARY | |||
|
PHENMETRAZINE
Created by
admin on Fri Dec 15 15:28:27 GMT 2023 , Edited by admin on Fri Dec 15 15:28:27 GMT 2023
|
PRIMARY | |||
|
XA501VL3VR
Created by
admin on Fri Dec 15 15:28:27 GMT 2023 , Edited by admin on Fri Dec 15 15:28:27 GMT 2023
|
PRIMARY | |||
|
100000082257
Created by
admin on Fri Dec 15 15:28:27 GMT 2023 , Edited by admin on Fri Dec 15 15:28:27 GMT 2023
|
PRIMARY | |||
|
1618-50-4
Created by
admin on Fri Dec 15 15:28:27 GMT 2023 , Edited by admin on Fri Dec 15 15:28:27 GMT 2023
|
PRIMARY | |||
|
C66372
Created by
admin on Fri Dec 15 15:28:27 GMT 2023 , Edited by admin on Fri Dec 15 15:28:27 GMT 2023
|
PRIMARY | |||
|
12314141
Created by
admin on Fri Dec 15 15:28:27 GMT 2023 , Edited by admin on Fri Dec 15 15:28:27 GMT 2023
|
PRIMARY | |||
|
SUB09769MIG
Created by
admin on Fri Dec 15 15:28:27 GMT 2023 , Edited by admin on Fri Dec 15 15:28:27 GMT 2023
|
PRIMARY | |||
|
205-143-4
Created by
admin on Fri Dec 15 15:28:27 GMT 2023 , Edited by admin on Fri Dec 15 15:28:27 GMT 2023
|
PRIMARY | |||
|
553
Created by
admin on Fri Dec 15 15:28:27 GMT 2023 , Edited by admin on Fri Dec 15 15:28:27 GMT 2023
|
PRIMARY | |||
|
3156
Created by
admin on Fri Dec 15 15:28:27 GMT 2023 , Edited by admin on Fri Dec 15 15:28:27 GMT 2023
|
PRIMARY | |||
|
DTXSID5023455
Created by
admin on Fri Dec 15 15:28:27 GMT 2023 , Edited by admin on Fri Dec 15 15:28:27 GMT 2023
|
PRIMARY | |||
|
2133
Created by
admin on Fri Dec 15 15:28:27 GMT 2023 , Edited by admin on Fri Dec 15 15:28:27 GMT 2023
|
PRIMARY | |||
|
8133
Created by
admin on Fri Dec 15 15:28:27 GMT 2023 , Edited by admin on Fri Dec 15 15:28:27 GMT 2023
|
PRIMARY | RxNorm | ||
|
CHEMBL1201208
Created by
admin on Fri Dec 15 15:28:27 GMT 2023 , Edited by admin on Fri Dec 15 15:28:27 GMT 2023
|
PRIMARY | |||
|
D010633
Created by
admin on Fri Dec 15 15:28:27 GMT 2023 , Edited by admin on Fri Dec 15 15:28:27 GMT 2023
|
PRIMARY | |||
|
m8621
Created by
admin on Fri Dec 15 15:28:27 GMT 2023 , Edited by admin on Fri Dec 15 15:28:27 GMT 2023
|
PRIMARY | Merck Index | ||
|
134-49-6
Created by
admin on Fri Dec 15 15:28:27 GMT 2023 , Edited by admin on Fri Dec 15 15:28:27 GMT 2023
|
NON-SPECIFIC STEREOCHEMISTRY | |||
|
DB00830
Created by
admin on Fri Dec 15 15:28:27 GMT 2023 , Edited by admin on Fri Dec 15 15:28:27 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)